Scheriproct 1mg + 1mg suppositories

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Prednisolone; Cinchocaine hydrochloride

Available from:

Bayer Limited

ATC code:

C05AA; C05AA04

INN (International Name):

Prednisolone; Cinchocaine hydrochloride

Dosage:

1 mg/1 milligram(s)

Pharmaceutical form:

Suppository

Prescription type:

Product subject to prescription which may not be renewed (A)

Therapeutic area:

Corticosteroids; prednisolone

Authorization status:

Marketed

Authorization date:

1978-04-01

Patient Information leaflet

Bayer Limited
The Atrium
Blackthorn Road
Dublin 18
Telephone:
[phone]
Fax:
[phone]
www.bayer.ie
15660
PATIENT INFORMATION
LEAFLET
SCHERIPROCT
® 1.5 MG/G +
5
MG/G RECTAL OINTMENT
SCHERIPROCT
® 1 MG + 1 MG
SUPPOSITORIES
PREDNISOLONE, CINCHOCAINE
HYDROCHLORIDE
READ ALL OF THIS LEAFLET CAREFULLY
BEFORE YOU START USING THIS
MEDICINE.

Keep this leaflet. You may need
to read it again.

If you have any further questions,
ask your doctor or pharmacist.

This medicine has been
prescribed for you. Do not pass it
on to others. It may harm them,
even if their symptoms are the
same as yours.

If you experience any side effect
and this becomes serious, tell
your doctor or pharmacist.
IN THIS LEAFLET:
1.
WHAT SCHERIPROCT IS AND WHAT
IT IS USED FOR
2.
BEFORE YOU USE SCHERIPROCT
3.
HOW TO USE SCHERIPROCT
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE SCHERIPROCT
6.
FURTHER INFORMATION
1.
WHAT SCHERIPROCT IS AND WHAT
IT IS USED FOR
Scheriproct contains a substance
which reduces inflammation
(prednisolone), and a local
anaesthetic (cinchocaine) which
relieves pain.
This medicine is used for the relief of
the inflammation, swelling, itching and
soreness of piles (haemorrhoids) and
to relieve itching of the anus (back
passage). It is used short-term usually
for 5 to 7 days.
2.
BEFORE YOU USE SCHERIPROCT
DO NOT USE SCHERIPROCT IF YOU:

are allergic (hypersensitive) to
prednisolone caproate, cinchocaine
hydrochloride, other local
anaesthetics or any of the other
ingredients of Scheriproct.

have a viral infection (e.g. herpes,
shingles, chicken-pox)

have any bacterial or fungal
infections of the skin for which you are
not receiving treatment
TAKE SPECIAL CARE WITH SCHERIPROCT

Long-term continuous treatment
should be avoided because it can
cause the skin to thin and
deteriorate in the affected area
(see section 4. “Possible Side
Effects”) and some of the medicine
may be absorbed into the blood
stream.

If the area treated with Scheriproct
is also infected your doctor should
prescribe another me

Summary of Product characteristics

HealthProductsRegulatoryAuthority
16April2019
CRN008LLS
Page1of4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Scheriproct1mg+1mgsuppositories
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Eachsuppositorycontainsprednisolonecaproateequivalentto1mgprednisoloneand1mgcinchocainehydrochloride.
Forafulllistofexcipients,seesection6.1.
3 PHARMACEUTICAL FORM
Suppository
Whitetoyellowishsuppositories.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Inthemanagementofsymptomsofinternalorexternalhaemorrhoids,analfissuresandproctitis.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
TheanalregionshouldbecleanedthoroughlybeforeusingScheriproct,whichisbestappliedafterdefaecation.
Onesuppositorydailyasdirected.Ifsymptomsaresevereonesuppositorytwoorthreetimesonthefirstday.
Onlyonthefirst
daymaymorethan1suppositorybeusedifthesymptomsaresevere.
Durationoftreatmentshouldnotusuallyexceed1week.
Specifictreatmentoftheconditiongivingrisetothehaemorrhoidsmayberequired.
4.3 CONTRAINDICATIONS
Useinthepresenceofuntreatedinfectionsofbacterial,viral,tuberculousorfungalorigin.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Additionalspecifictherapyisrequiredinbacterialand/orfungalinfections.
Therehavebeenafewreportsintheliteratureofthedevelopmentofcataractsinpatientswhohavebeenusingcorticosteroids
forprolongedperiodsoftime.Althoughitisnotpossibletoruleoutsystemiccorticosteroidsasaknownfactor,prescribers
shouldbeawareofthepossibleroleofcorticosteroidsincataractdevelop